Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
As the 150-day ordinary Diet session ended on June 1, a Lower House health committee voted to continue its review of a bill on the legal regulation of clinical research during the parliament’s recess.The bill will continue to be placed…
To read the full story
Related Article
- Clinical Research Law Promulgated
April 17, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Clinical Research Bill Passes Lower House
March 23, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
REGULATORY
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…